Developer docs
API playgroundTry for free, no card

Search company profiles

Paragonix Technologies

Full company profile

uuid00009yz

Namestring
Paragonix Technologies
Legal namestring
PARAGONIX TECHNOLOGIES, INC.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Paragonix Technologies is a US-based medical device company specializing in advanced organ preservation and transport systems for solid organ transplantation. Founded in 2010 (with commercial operations beginning in 2018) and headquartered in Waltham, Massachusetts, the company sells a portfolio of six FDA-cleared and five CE-marked preservation devices covering heart (SherpaPak), lung (LUNGguard and BAROguard), liver (LIVERguard), pancreas (PancreasPak), and kidney (KidneyVault) to transplant centers and federally designated Organ Procurement Organizations (OPOs). The underlying technology replaces traditional ice-based transport with controlled hypothermic preservation maintaining organs at 4-8°C to prevent freezing injury, combined with a digital platform (Paragonix App and Web Portal) that provides real-time GPS tracking, temperature monitoring, and HIPAA-compliant case messaging.

The company's commercial ecosystem is reinforced by 24/7 clinical procurement services, a nationwide distribution fleet, seven procurement hubs staffed by 50+ clinical specialists, and the GUARDIAN clinical registries (Heart, Lung, Liver) — described as the largest observational database studying post-transplant impact of organ preservation. Business model is primarily direct enterprise sales of hardware devices to transplant centers and OPOs through quote-based multi-year agreements, complemented by clinical support services and managed logistics. Following its September 2024 acquisition by Swedish medical technology conglomerate Getinge AB for approximately USD 477 million, Paragonix operates as a Getinge subsidiary, gaining access to global distribution infrastructure while maintaining its product brand identity and clinical focus.

Short descriptiontext

Paragonix Technologies develops FDA-cleared and CE-marked controlled hypothermic organ preservation devices for heart, lung, liver, pancreas, and kidney transplantation, serving transplant centers and Organ Procurement Organizations with a digital tracking platform and 24/7 clinical support; the company operates as a subsidiary of Getinge AB following its September 2024 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ preservation devices, transplant medical devices, hypothermic preservation systems, donor organ transport, clinical procurement services
Industry1 code
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices - Organ Preservation and Transport
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Organ Preservation Devices
TypeHardware Sales
Description

Sale of FDA-cleared and CE-marked organ preservation devices including SherpaPak, LUNGguard, LIVERguard, BAROguard, PancreasPak, and KidneyVault for cardiothoracic and abdominal transplantation

paragonixtechnologies.com
2Clinical Support Services
TypeProfessional Services
Description

24/7 clinical support services provided nationwide including on-call procurement support and clinical coordination for transplant centers

paragonixtechnologies.com
3Distribution Fleet Services
TypeManaged Services
Description

Dedicated fleet providing organ preservation technology, logistics, and clinical expertise at point of care across the United States

globenewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise pricing for transplant centers and OPOs
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Devices are sold directly to transplant centers and Organ Procurement Organizations through enterprise agreements.

paragonixtechnologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1SherpaPak
Description

Cardiac Transport System - FDA-cleared and CE-marked heart preservation device

paragonixtechnologies.com
+5 more records
Core offering1 text field

Paragonix Technologies manufactures and sells FDA-cleared and CE-marked medical devices for Advanced Organ Preservation during donor organ transport, including SherpaPak (cardiac), LUNGguard and BAROguard (lung), LIVERguard (liver), PancreasPak (pancreas), and KidneyVault (kidney). The devices maintain controlled hypothermic temperatures (4-8°C) to prevent cold injury, and are complemented by a proprietary digital tracking platform (Paragonix App and Web Portal) and 24/7 clinical procurement support services sold to transplant centers and Organ Procurement Organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 67% reduction in Severe Primary Graft Dysfunction (PGD) in heart transplant patients using SherpaPak vs. conventional ice storage (p=0.011)
+5 more records
Product overview1 text field

Paragonix Technologies offers a comprehensive Advanced Organ Preservation ecosystem consisting of six FDA-cleared and five CE-marked medical devices for cardiothoracic and abdominal organ transplantation. The core product portfolio includes SherpaPak® (cardiac), LUNGguard® and BAROguard® (lung), LIVERguard® (liver), PancreasPak™ (pancreas), and KidneyVault® (kidney) preservation systems. These devices maintain consistent controlled hypothermic temperatures to prevent organ freezing during transport. The product ecosystem is complemented by a proprietary digital platform (Paragonix App and Web Portal) providing real-time GPS tracking, temperature monitoring, and case coordination, supported by 24/7 clinical procurement services and the GUARDIAN clinical registries—the world's largest observational database for organ preservation outcomes research.

Product and service9 records
1SherpaPak Cardiac Transport System
CategoryCardiothoracic Transplantation Devices
Description

FDA-cleared and CE-marked heart preservation device that maintains donor hearts at controlled hypothermic temperatures (4-8°C) during transport. Features TempLock thermal control technology and is intended for up to 4 hours of static hypothermic preservation.

2LUNGguard Organ Preservation System
CategoryCardiothoracic Transplantation Devices
Description

FDA-cleared and CE-marked lung preservation device that maintains donor lungs at controlled hypothermic temperatures during transport. Intended for up to 8 hours of static hypothermic preservation.

3BAROguard Donor Lung Preservation System
CategoryCardiothoracic Transplantation Devices
Description

FDA-cleared and CE-marked next-generation lung preservation device combining advanced hypothermic preservation with automated continuous active airway pressure control. Maintains optimal temperature and clinically recommended inflation pressure for donor lungs throughout transport. Recognized on TIME's 2024 Best Inventions List.

4LIVERguard Donor Liver Preservation System
CategoryAbdominal Transplantation Devices
Description

FDA-cleared and CE-marked liver preservation device for static hypothermic preservation of donor livers during transportation. Intended for up to 15 hours of preservation time.

5PancreasPak Organ Preservation System
CategoryAbdominal Transplantation Devices
Description

FDA-cleared organ preservation system for donor pancreas transportation. Can maintain donor organ storage temperature between 4°C and 8°C through 21 hours.

6KidneyVault Portable Renal Perfusion System
CategoryAbdominal Transplantation Devices
Description

FDA-cleared pulsatile hypothermic machine perfusion system for kidney preservation and transportation. Can maintain donor kidney storage temperature between 4°C and 8°C through 24 hours. Reached 1,000 clinical cases milestone in March 2026.

7Paragonix Digital Hub & App
CategoryDigital Services
Description

Mobile application and web portal providing real-time tracking of organ location via GPS, temperature monitoring, HIPAA-compliant messaging for case coordination, and access to historical case data and trends.

8Clinical Procurement Services
CategoryClinical Services
Description

24/7 clinical support services providing on-call procurement or support customized to transplant center needs. Includes nationwide network of experienced clinical specialists and organ procurement teams.

9Paragonix Distribution Fleet
CategoryLogistics Services
Description

Nationwide supply chain initiative featuring dedicated fleet vehicles to improve access to organ preservation technologies and clinical support. Vehicles deployed in Florida and California.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Collaboration announced May 2026 to launch the CONCERT-DCD clinical trial aimed at maximizing heart transplant utilization through donation after circulatory death (DCD) donor hearts. University of Washington serving as clinical trial sponsor.

2Gravitas Surgical
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Strategic partnership announced November 2025 to enhance donor lung preservation and viability on the US West Coast. Coincided with Gravitas's launch of an Ex Vivo Lung Perfusion program in Phoenix, Arizona. Collaboration aims to improve transplant success rates and expand access to lung transplants in the Western United States.

globenewswire.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

OPO partnership supporting Paragonix's 100th kidney transplant case with FDA-cleared KidneyVault system. Tennessee Donor Services serves over 6 million people across Tennessee and Virginia.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

Strategic partnership announced September 2025 to enhance clinical utilization of complex donor kidneys via the Paragonix KidneyVault Portable Renal Perfusion System. Federally designated OPO serving California and Nevada.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Partnership supporting groundbreaking kidney transplant case with KidneyVault system maintaining continuous perfusion over 30 hours with total cold ischemic time exceeding 46 hours. Demonstrates technology's capability with medically complex donor kidneys.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

Groundbreaking initiative to place high-risk donor kidneys, expanding transplant opportunities for patients in need. Combines Sierra Donor Services OPO expertise with UCI Health transplant program and Paragonix KidneyVault technology.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-10-29
Description

North Carolina's largest organ donation and tissue recovery organization partnered with Paragonix for first successful liver transplant using LIVERguard technology. HonorBridge facilitated donor liver transport from North Carolina to Tampa General Hospital.

Strategic tierCoreTypeOthersAnnounced on2024-09-01
Description

Getinge acquired Paragonix Technologies for approximately USD 477 million in September 2024, marking Getinge's entry into the organ preservation and transportation market. The acquisition aims to expand Getinge's portfolio and leverage Paragonix's strong growth and innovative products. Paragonix operates as a Getinge company following the acquisition.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-08-29
Description

Launch of new donor organ courier service in partnership with NORA to establish cost-effective transport alternative. Combines Paragonix preservation technology with NORA's logistics expertise.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-09-15
Description

Collaboration on novel NRP-DCD (Normothermic Regional Perfusion - Donation After Circulatory Death) method to expand organ donor pool. Combines UNMC's NRP technique with Paragonix SherpaPak for DCD heart recovery and transport. IRB approved study registered with NIH (NCT05038943).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
1TransMedics Group
TypeDirect peer
Description

TransMedics develops the Organ Care System (OCS), a normothermic machine perfusion platform for heart, lung, and liver preservation. It is the most direct competitor to Paragonix in multi-organ transplant preservation, with both companies targeting the same transplant centers and OPOs with fundamentally different preservation approaches.

TypeDirect peer
Description

Organ Recovery Systems manufactures the LifePort Kidney Transporter, a hypothermic machine perfusion device for donor kidneys. It is the most direct competitor to Paragonix's KidneyVault in the kidney preservation segment and shares the hypothermic perfusion paradigm.

TypeDirect peer
Description

XVIVO Perfusion (Sweden) develops organ preservation and perfusion solutions, most notably for lung transplantation (Lung Assist), and has expanded into heart and liver perfusion. As a European competitor with overlapping transplant indications, XVIVO is a relevant comparable in international markets.

TypeDirect peer
Description

OrganOx (UK) developed the metra normothermic liver perfusion device, a direct alternative to Paragonix's LIVERguard for liver preservation. Both companies compete in the advanced liver preservation market with different technology approaches (normothermic vs. static hypothermic).

TypeEmerging player
Description

Bridge to Life manufactures cold storage and machine perfusion solutions for organ preservation, including Belzer UW Cold Storage and LifeCradle perfusion devices. It competes primarily in traditional cold storage and represents a lower-cost alternative to Paragonix's controlled hypothermic technology.

6Institut Georges Lopez (IGL)
TypeEmerging player
Description

IGL produces preservation solutions (e.g., IGL-1, SCOT 30) and perfusion devices used in organ transplantation. It is a European-headquartered competitor offering both solutions and equipment, partially overlapping with Paragonix's perfusion/preservation offering.

7Preservation Solutions
TypeEmerging player
Description

Preservation Solutions manufactures cold storage organ preservation solutions (e.g., Euro-Collins, Custodiol HTK). It is a niche player in the broader organ preservation ecosystem and an indirect competitor as it supplies the traditional ice-based cold storage workflow that Paragonix devices aim to replace.

8Global Transplant Solutions
TypeEmerging player
Description

Global Transplant Solutions manufactures the LifePort disposable perfusion circuits and related organ transport products. It is an emerging competitor in the kidney and broader organ preservation equipment space with direct overlap to Paragonix's perfusion product line.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Paragonix Technologies

Medical Devices - Organ Preservation and Transportparagonixtechnologies.com

Paragonix Technologies develops FDA-cleared and CE-marked controlled hypothermic organ preservation devices for heart, lung, liver, pancreas, and kidney transplantation, serving transplant centers and Organ Procurement Organizations with a digital tracking platform and 24/7 clinical support; the company operates as a subsidiary of Getinge AB following its September 2024 acquisition.

What Paragonix Technologies does

Paragonix Technologies is a US-based medical device company specializing in advanced organ preservation and transport systems for solid organ transplantation. Founded in 2010 (with commercial operations beginning in 2018) and headquartered in Waltham, Massachusetts, the company sells a portfolio of six FDA-cleared and five CE-marked preservation devices covering heart (SherpaPak), lung (LUNGguard and BAROguard), liver (LIVERguard), pancreas (PancreasPak), and kidney (KidneyVault) to transplant centers and federally designated Organ Procurement Organizations (OPOs). The underlying technology replaces traditional ice-based transport with controlled hypothermic preservation maintaining organs at 4-8°C to prevent freezing injury, combined with a digital platform (Paragonix App and Web Portal) that provides real-time GPS tracking, temperature monitoring, and HIPAA-compliant case messaging.

The company's commercial ecosystem is reinforced by 24/7 clinical procurement services, a nationwide distribution fleet, seven procurement hubs staffed by 50+ clinical specialists, and the GUARDIAN clinical registries (Heart, Lung, Liver) — described as the largest observational database studying post-transplant impact of organ preservation. Business model is primarily direct enterprise sales of hardware devices to transplant centers and OPOs through quote-based multi-year agreements, complemented by clinical support services and managed logistics. Following its September 2024 acquisition by Swedish medical technology conglomerate Getinge AB for approximately USD 477 million, Paragonix operates as a Getinge subsidiary, gaining access to global distribution infrastructure while maintaining its product brand identity and clinical focus.

Paragonix Technologies firmographics

Firmographics
Name
Paragonix Technologies
Legal name
PARAGONIX TECHNOLOGIES, INC.
Website
https://paragonixtechnologies.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
101–250 employees
Short description
Paragonix Technologies develops FDA-cleared and CE-marked controlled hypothermic organ preservation devices for heart, lung, liver, pancreas, and kidney transplantation, serving transplant centers and Organ Procurement Organizations with a digital tracking platform and 24/7 clinical support; the company operates as a subsidiary of Getinge AB following its September 2024 acquisition.
Ownership category
akta.pro rank

Paragonix Technologies industry classification

Industry
Product category
Medical Devices - Organ Preservation and Transport
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Organ preservation devices
  • Transplant medical devices
  • Hypothermic preservation systems
  • Donor organ transport
  • Clinical procurement services

Where Paragonix Technologies is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Paragonix Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Organ Preservation Devices: Sale of FDA-cleared and CE-marked organ preservation devices including SherpaPak, LUNGguard, LIVERguard, BAROguard, PancreasPak, and KidneyVault for cardiothoracic and abdominal transplantation
  2. Clinical Support Services: 24/7 clinical support services provided nationwide including on-call procurement support and clinical coordination for transplant centers
  3. Distribution Fleet Services: Dedicated fleet providing organ preservation technology, logistics, and clinical expertise at point of care across the United States

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise pricing for transplant centers and OPOs

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Paragonix Technologies product offering

Product offering

Core offering

Paragonix Technologies manufactures and sells FDA-cleared and CE-marked medical devices for Advanced Organ Preservation during donor organ transport, including SherpaPak (cardiac), LUNGguard and BAROguard (lung), LIVERguard (liver), PancreasPak (pancreas), and KidneyVault (kidney). The devices maintain controlled hypothermic temperatures (4-8°C) to prevent cold injury, and are complemented by a proprietary digital tracking platform (Paragonix App and Web Portal) and 24/7 clinical procurement support services sold to transplant centers and Organ Procurement Organizations.

Product overview

Paragonix Technologies offers a comprehensive Advanced Organ Preservation ecosystem consisting of six FDA-cleared and five CE-marked medical devices for cardiothoracic and abdominal organ transplantation. The core product portfolio includes SherpaPak® (cardiac), LUNGguard® and BAROguard® (lung), LIVERguard® (liver), PancreasPak™ (pancreas), and KidneyVault® (kidney) preservation systems. These devices maintain consistent controlled hypothermic temperatures to prevent organ freezing during transport. The product ecosystem is complemented by a proprietary digital platform (Paragonix App and Web Portal) providing real-time GPS tracking, temperature monitoring, and case coordination, supported by 24/7 clinical procurement services and the GUARDIAN clinical registries—the world's largest observational database for organ preservation outcomes research.

Differentiator

Problem solved

Functional benefit

Brands

  • SherpaPak: Cardiac Transport System - FDA-cleared and CE-marked heart preservation device
  • LUNGguard
  • BAROguard
  • LIVERguard
  • PancreasPak
  • KidneyVault

Products and services

  • SherpaPak Cardiac Transport System FDA-cleared and CE-marked heart preservation device that maintains donor hearts at controlled hypothermic temperatures (4-8°C) during transport. Features TempLock thermal control technology and is intended for up to 4 hours of static hypothermic preservation.
  • LUNGguard Organ Preservation System FDA-cleared and CE-marked lung preservation device that maintains donor lungs at controlled hypothermic temperatures during transport. Intended for up to 8 hours of static hypothermic preservation.
  • BAROguard Donor Lung Preservation System FDA-cleared and CE-marked next-generation lung preservation device combining advanced hypothermic preservation with automated continuous active airway pressure control. Maintains optimal temperature and clinically recommended inflation pressure for donor lungs throughout transport. Recognized on TIME's 2024 Best Inventions List.
  • LIVERguard Donor Liver Preservation System FDA-cleared and CE-marked liver preservation device for static hypothermic preservation of donor livers during transportation. Intended for up to 15 hours of preservation time.
  • PancreasPak Organ Preservation System FDA-cleared organ preservation system for donor pancreas transportation. Can maintain donor organ storage temperature between 4°C and 8°C through 21 hours.
  • KidneyVault Portable Renal Perfusion System FDA-cleared pulsatile hypothermic machine perfusion system for kidney preservation and transportation. Can maintain donor kidney storage temperature between 4°C and 8°C through 24 hours. Reached 1,000 clinical cases milestone in March 2026.
  • Paragonix Digital Hub & App Mobile application and web portal providing real-time tracking of organ location via GPS, temperature monitoring, HIPAA-compliant messaging for case coordination, and access to historical case data and trends.
  • Clinical Procurement Services 24/7 clinical support services providing on-call procurement or support customized to transplant center needs. Includes nationwide network of experienced clinical specialists and organ procurement teams.
  • Paragonix Distribution Fleet Nationwide supply chain initiative featuring dedicated fleet vehicles to improve access to organ preservation technologies and clinical support. Vehicles deployed in Florida and California.

Quantifiable outcome

  • 67% reduction in Severe Primary Graft Dysfunction (PGD) in heart transplant patients using SherpaPak vs. conventional ice storage (p=0.011)
  • +5 more outcomes

Companies that use Paragonix Technologies

Customer profile

Named customers16 records

Segments5 records

Ideal customer profiles4 records

Paragonix Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature10 records

Paragonix Technologies partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, strategic and core.

  • UW MedicinemajorStrategic or Co-development Partner · 27 May 2026Collaboration announced May 2026 to launch the CONCERT-DCD clinical trial aimed at maximizing heart transplant utilization through donation after circulatory death (DCD) donor hearts. University of Washington serving as clinical trial sponsor.
  • Gravitas SurgicalmajorStrategic or Co-development Partner · 18 November 2025Strategic partnership announced November 2025 to enhance donor lung preservation and viability on the US West Coast. Coincided with Gravitas's launch of an Ex Vivo Lung Perfusion program in Phoenix, Arizona. Collaboration aims to improve transplant success rates and expand access to lung transplants in the Western United States.
  • Tennessee Donor ServicesstrategicStrategic or Co-development Partner · 4 November 2025OPO partnership supporting Paragonix's 100th kidney transplant case with FDA-cleared KidneyVault system. Tennessee Donor Services serves over 6 million people across Tennessee and Virginia.
  • Donor Network WestmajorStrategic or Co-development Partner · 17 September 2025Strategic partnership announced September 2025 to enhance clinical utilization of complex donor kidneys via the Paragonix KidneyVault Portable Renal Perfusion System. Federally designated OPO serving California and Nevada.
  • Tampa General Hospital Transplant InstitutemajorStrategic or Co-development Partner · 2 September 2025Partnership supporting groundbreaking kidney transplant case with KidneyVault system maintaining continuous perfusion over 30 hours with total cold ischemic time exceeding 46 hours. Demonstrates technology's capability with medically complex donor kidneys.
  • Sierra Donor Services and UCI HealthstrategicStrategic or Co-development Partner · 29 May 2025Groundbreaking initiative to place high-risk donor kidneys, expanding transplant opportunities for patients in need. Combines Sierra Donor Services OPO expertise with UCI Health transplant program and Paragonix KidneyVault technology.
  • HonorBridgestrategicStrategic or Co-development Partner · 29 October 2024North Carolina's largest organ donation and tissue recovery organization partnered with Paragonix for first successful liver transplant using LIVERguard technology. HonorBridge facilitated donor liver transport from North Carolina to Tampa General Hospital.
  • GetingecoreOthers · 1 September 2024Getinge acquired Paragonix Technologies for approximately USD 477 million in September 2024, marking Getinge's entry into the organ preservation and transportation market. The acquisition aims to expand Getinge's portfolio and leverage Paragonix's strong growth and innovative products. Paragonix operates as a Getinge company following the acquisition.
  • Nationwide Organ Recovery Transport Alliance (NORA)strategicStrategic or Co-development Partner · 29 August 2024Launch of new donor organ courier service in partnership with NORA to establish cost-effective transport alternative. Combines Paragonix preservation technology with NORA's logistics expertise.
  • University of Nebraska Medical CentermajorStrategic or Co-development Partner · 15 September 2021Collaboration on novel NRP-DCD (Normothermic Regional Perfusion - Donation After Circulatory Death) method to expand organ donor pool. Combines UNMC's NRP technique with Paragonix SherpaPak for DCD heart recovery and transport. IRB approved study registered with NIH (NCT05038943).

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Paragonix Technologies competitors and assessment

Company assessment

Direct peers

  • TransMedics Group: TransMedics develops the Organ Care System (OCS), a normothermic machine perfusion platform for heart, lung, and liver preservation. It is the most direct competitor to Paragonix in multi-organ transplant preservation, with both companies targeting the same transplant centers and OPOs with fundamentally different preservation approaches.
  • Organ Recovery Systems: Organ Recovery Systems manufactures the LifePort Kidney Transporter, a hypothermic machine perfusion device for donor kidneys. It is the most direct competitor to Paragonix's KidneyVault in the kidney preservation segment and shares the hypothermic perfusion paradigm.
  • XVIVO Perfusion: XVIVO Perfusion (Sweden) develops organ preservation and perfusion solutions, most notably for lung transplantation (Lung Assist), and has expanded into heart and liver perfusion. As a European competitor with overlapping transplant indications, XVIVO is a relevant comparable in international markets.
  • OrganOx: OrganOx (UK) developed the metra normothermic liver perfusion device, a direct alternative to Paragonix's LIVERguard for liver preservation. Both companies compete in the advanced liver preservation market with different technology approaches (normothermic vs. static hypothermic).

Emerging players

  • Bridge to Life: Bridge to Life manufactures cold storage and machine perfusion solutions for organ preservation, including Belzer UW Cold Storage and LifeCradle perfusion devices. It competes primarily in traditional cold storage and represents a lower-cost alternative to Paragonix's controlled hypothermic technology.
  • Institut Georges Lopez (IGL): IGL produces preservation solutions (e.g., IGL-1, SCOT 30) and perfusion devices used in organ transplantation. It is a European-headquartered competitor offering both solutions and equipment, partially overlapping with Paragonix's perfusion/preservation offering.
  • Preservation Solutions: Preservation Solutions manufactures cold storage organ preservation solutions (e.g., Euro-Collins, Custodiol HTK). It is a niche player in the broader organ preservation ecosystem and an indirect competitor as it supplies the traditional ice-based cold storage workflow that Paragonix devices aim to replace.
  • Global Transplant Solutions: Global Transplant Solutions manufactures the LifePort disposable perfusion circuits and related organ transport products. It is an emerging competitor in the kidney and broader organ preservation equipment space with direct overlap to Paragonix's perfusion product line.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Paragonix Technologies social profiles

Digital presence

Paragonix Technologies compliance and trust

Trust signal

Compliance6 records

Paragonix Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Paragonix Technologies leadership team

Management profile

Number of profiles

Profiles10 records

Paragonix Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Paragonix Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paragonix Technologies

What does Paragonix Technologies do?

Paragonix Technologies manufactures and sells FDA-cleared and CE-marked medical devices for Advanced Organ Preservation during donor organ transport, including SherpaPak (cardiac), LUNGguard and BAROguard (lung), LIVERguard (liver), PancreasPak (pancreas), and KidneyVault (kidney). The devices maintain controlled hypothermic temperatures (4-8°C) to prevent cold injury, and are complemented by a proprietary digital tracking platform (Paragonix App and Web Portal) and 24/7 clinical procurement support services sold to transplant centers and Organ Procurement Organizations.

Is Paragonix Technologies a public or private company?

Paragonix Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Paragonix Technologies founded?

Paragonix Technologies was founded in 2018. It employs 101 to 250 people.

Where is Paragonix Technologies based?

Paragonix Technologies is headquartered in Waltham, United States, in the North America region.

How does Paragonix Technologies make money?

Three revenue lines are on record. Organ Preservation Devices are the primary driver. The others are clinical Support Services and distribution Fleet Services.

Who are Paragonix Technologies's main competitors?

Direct peers on record are TransMedics Group, Organ Recovery Systems, XVIVO Perfusion and OrganOx. Emerging players are Bridge to Life, Institut Georges Lopez (IGL), Preservation Solutions and Global Transplant Solutions.

Does Paragonix Technologies have an API?

No public API is recorded for Paragonix Technologies.

What industry is Paragonix Technologies in?

Paragonix Technologies's product category is Medical Devices - Organ Preservation and Transport. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Med-Tech InsightsLandmark kidney transplants set benchmark for long-distance organ transportParagonix Technologies completed two kidney transplants using its KidneyVault system, transporting kidneys from Hawaii to New York and Connecticut. The left kidney traveled 4,311.2 nautical miles and the right 4,353.8, with a total ischemic time of 18 hours 29 minutes. The Connecticut case is the longest recovery and transport on record for Legacy of Life Hawaii.Mpo-magNew Lung Preservation Studies Reveal Insights of Optimizing Temperature, Airway Pressure ControlA multi-center analysis of 499 adult lung transplant recipients found that preserving lungs at 6-8°C reduced rejection and intervention rates, while 8-10°C showed worse outcomes. Active airway pressure management via BAROguard also reduced mechanical support and inflammation, especially in long-distance transplants.GlobeNewswireParagonix LIVERguard System Shown to Safely Extend Ischemic Times Enabling Expanded Utilization of Donor LiversParagonix presented clinical data at the 2026 American Transplant Congress showing its LIVERguard system safely extends cold ischemic time without compromising outcomes. The study of 1,477 patients from 13 centers found no increase in early complications and 100% three-month graft survival in DCD donors. The findings suggest expanded donor access via longer transport distances.MedCity NewsLeveraging Technology to Navigate the New Era of Continuous Organ DistributionOrgan preservation technology has advanced from simple ice coolers to high-tech systems that allow donor organs to be transported more safely over longer distances, with air transportation becoming increasingly common due to new federal guidelines and changes in transplant allocation systems moving toward continuous distribution models. The article discusses how real-time tracking, GPS-linked communication tools, and streamlined logistics are needed to support this evolving landscape, as many organs now travel unaccompanied and clinicians require live data to monitor conditions. Paragonix Technologies, a company specializing in organ preservation used at over 200 transplant centers globally, was acquired by Getinge in September 2024.BostonGlobe.comHigh-stakes world of organ transplants sees a revolution, led by two Mass. companiesTwo Massachusetts companies, Paragonix and TransMedics, have developed high-tech containers that keep donor organs viable during long-distance transport. The devices extend organ viability beyond the traditional four-to-six-hour limit, enabling more transplants. Over 100,000 people in the US wait for organs, and these technologies could reduce waste.GlobeNewswireNew Lung Preservation Studies Showcase Key Insights of Optimizing Temperature and Airway Pressure ControlParagonix Technologies presented new clinical research at the 2026 ISHLT Annual Meeting demonstrating that their LUNGguard and BAROguard organ preservation systems improve lung transplant outcomes. A multi-center analysis of 499 adult lung transplant recipients across 18 centers found that controlled 6-8°C preservation temperatures and active airway pressure management significantly reduced post-transplant rejection, mechanical support needs, airway inflammation, and hospital length of stay. The findings support a shift toward actively managing physiological variables during organ transport, with statistically significant improvements observed even in higher-risk scenarios involving longer ischemic times and extended transport distances.GlobeNewswireNew Lung Preservation Studies Showcase Key Insights of Optimizing Temperature and Airway Pressure ControlParagonix Technologies presented new lung preservation data at the 2026 ISHLT meeting, showing controlled hypothermic preservation at 6-8°C and active airway pressure management improve outcomes. The multi-center analysis of 499 recipients found reduced rejection and intervention rates, with airway pressure control cutting mechanical support needs and hospital stays.GlobeNewswireParagonix Announces Technology Upgrade to Industry Leading SherpaPak® Cardiac Transport SystemParagonix Technologies announced TempLock, a thermal control upgrade to its SherpaPak Cardiac Transport System, unveiled at ISHLT 2026. The system maintains temperatures between 4-8°C over extended durations, addressing longer-distance procurement needs. The company cites improved transplant survival outcomes from its preservation technology.openPR.comEmerging Sub-Segments Transforming the Organ Transport Service Market LandscapeThe organ transport service market is projected to grow to $5.25 billion by 2030, representing a compound annual growth rate of 9.3%, driven by demand for faster organ delivery, smart tracking technologies, and international organ exchange programs. In August 2024, Sweden's Getinge AB acquired US-based Paragonix Technologies Inc. for approximately $477 million to strengthen its presence in the organ transplant ecosystem by integrating Paragonix's organ preservation and digital transport tracking technologies. Key emerging trends include real-time organ tracking systems and temperature-controlled transport containers that improve transplant outcomes by reducing delays and preserving organ viability.openPR.comAnalysis of Market Segments and Major Growth Areas in the Perfusion Systems IndustryThe Business Research Company released a market analysis report projecting the global perfusion systems market to reach $2.38 billion by 2030, growing at a compound annual growth rate of 10.5%, driven by investments in surgical infrastructure, demand for portable perfusion devices, and advancements in organ preservation technology. In September 2024, Swedish company Getinge AB acquired US-based Paragonix Technologies for $477 million to strengthen its position in the organ preservation and transport market. The report identifies key market segments including cardiopulmonary perfusion systems, ECMO platforms, and isolated organ perfusion systems, with hospitals and clinics as primary end-users.